"So while we'll be lowering the financial risk for these companies, we will not be lowering any standards of development, safety and efficacy." "The return on this investment to our country in terms of lives saved and economic confidence is far greater than that of any single vaccine developer," an official said. But for a COVID-19 vaccine, the official added, Operation Warp Speed and the federal government - not private companies - will be assuming the risk. Private-sector drug companies would not develop a drug in such a fashion, the first official said, due to the financial risk. "That capacity will be used for whatever vaccine is eventually successful, regardless of which firms have developed their capacity," that official said.
We will still complete all of the necessary clinical trials to determine safety and efficacy."Īnother senior administration official said that the manufacturing capacity for three to five selected candidates will be advanced while those vaccine candidates are still in development. "That is, when safety and efficacy have been demonstrated, there isn't a day's delay due to manufacturing ramp-up timelines. "We expect to be producing large quantities of vaccines while the clinical trials are still underway," one official said. In some cases, officials said, Operation Warp Speed will do them at the same time. Speaking on background during a conference call today, officials said that when creating a vaccine, things such as development, clinical trials and manufacturing typically would occur one after the other.
0 kommentar(er)
